TIDMONC

RNS Number : 8682L

Oncimmune Holdings PLC

15 September 2021

15 September 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Block Listing Six Monthly Return

Oncimmune makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements in respect of Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans (the "Share Option Plans").

 
 Name of applicant:                            Oncimmune Holdings plc 
 Name of scheme:                               Oncimmune Holdings Plc 2016 
                                                Unapproved and EMI Share Option 
                                                Plans 
                                              --------------------------------- 
 Period of return:                             16 March 2021 to 15 September 
                                                2021 
                                              --------------------------------- 
 Balance of unallotted securities 
  under scheme(s) from previous 
  return:                                       5,830,154 
                                              --------------------------------- 
 Plus: The amount by which the 
  block scheme(s) has been increased 
  since the date of the last return 
  (if any increase has been applied 
  for):                                        0 
                                              --------------------------------- 
 Less: Number of securities issued/allotted 
  under scheme(s) during period:               24,409 
                                              --------------------------------- 
 Equals: Balance under scheme(s) 
  not yet issued/allotted at end 
  of period:                                   5,805,745 
                                              ---------------------------------

For further information:

Oncimmune Holdings plc

Ron Kirschner, Company Secretary

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, James Hornigold

+44 (0)20 3829 5000

Singer Capital Markets (Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Nigel Birks

+44 (0)203 705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRDKPBKKBKDOCD

(END) Dow Jones Newswires

September 15, 2021 06:08 ET (10:08 GMT)

Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Oncimmune Charts.
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Oncimmune Charts.